Imaging and chemical biomarkers for assessing the effectiveness of therapy in the first European investigator-driven clinical trial investigating the benefits of hypothermia in ischaemic stroke patients

点击翻译按钮获取中文摘要

Hypothermia, entering phase III trial in Europe, has the potential to slow brain injury after stroke. It will allow existing thrombolytic therapies which restore critical brain blood flow to be used in many more patients than currently possible. However, hypothermia will soak up valuable resources if non-selectively applied to the ~15 million patients who have a stroke each year. We aim to identify biomarkers to test which patients will benefit most and permit the best resource allocation.